BR0307331A - Formulações granuladas a seco de azitromicina - Google Patents

Formulações granuladas a seco de azitromicina

Info

Publication number
BR0307331A
BR0307331A BR0307331-9A BR0307331A BR0307331A BR 0307331 A BR0307331 A BR 0307331A BR 0307331 A BR0307331 A BR 0307331A BR 0307331 A BR0307331 A BR 0307331A
Authority
BR
Brazil
Prior art keywords
azithromycin
mga
pharmaceutical formulation
forms
dry granulated
Prior art date
Application number
BR0307331-9A
Other languages
English (en)
Inventor
Barbara Alice Johnson
Ernest Shing Quan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0307331A publication Critical patent/BR0307331A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES GRANULADAS A SECO DE AZITROMICINA". Esta invenção refere-se a uma formulação farmacêutica, na forma de um comprimido, saqueta ou pó para forma de dosagem em suspensão, a qual compreende partículas granuladas secas de uma forma não di-hidratada de azitromicina e, facultativamente, um ou mais excipientes farmaceuticamente aceitáveis. Preferivelmente, a formulação farmacêutica é um comprimido contendo entre cerca de 40%, em massa, e cerca de 85%, em massa, de azitromicina não di-hidratada. Mais preferivelmente, a formulação farmacêutica contém azitromicina não di-hidratada selecionada de entre as formas B, D, E, F, G, H, J, M, N, 0, P, Q e R, ou suas misturas. Mesmo mais preferivelmente, a invenção diz respeito a uma formulação farmacêutica em que a dosagem de azitromicina é 250 mgA, 500 mgA, 600 mgA ou 1000 mgA. A presente invenção diz ainda respeito a uma partícula de azitromicina granulada a seco, compreendendo uma forma de azitromicina, selecionada das formas D, E, F, G, H, J, M, N, 0, P, Q e R e misturas de formas não di-hidratadas e pelo menos um excipiente farmaceuticamente aceitável.
BR0307331-9A 2002-02-01 2003-01-20 Formulações granuladas a seco de azitromicina BR0307331A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35404102P 2002-02-01 2002-02-01
PCT/IB2003/000212 WO2003063838A1 (en) 2002-02-01 2003-01-20 Dry granulated formulations of azithromycin

Publications (1)

Publication Number Publication Date
BR0307331A true BR0307331A (pt) 2004-12-07

Family

ID=27663280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307331-9A BR0307331A (pt) 2002-02-01 2003-01-20 Formulações granuladas a seco de azitromicina

Country Status (18)

Country Link
US (1) US7438924B2 (pt)
EP (1) EP1478347A1 (pt)
JP (1) JP2005526020A (pt)
KR (1) KR100676025B1 (pt)
CN (1) CN1646104A (pt)
AR (1) AR038371A1 (pt)
AU (1) AU2003201146B2 (pt)
BR (1) BR0307331A (pt)
CA (1) CA2474809A1 (pt)
CO (1) CO5611118A2 (pt)
MX (1) MXPA04007427A (pt)
NO (1) NO20043644L (pt)
NZ (1) NZ534234A (pt)
PL (1) PL372394A1 (pt)
RU (1) RU2283092C2 (pt)
TW (1) TW200306865A (pt)
WO (1) WO2003063838A1 (pt)
ZA (1) ZA200405805B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
JP3444874B1 (ja) * 2002-12-02 2003-09-08 高砂香料工業株式会社 顆粒状香料およびその製造方法
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
JP2007513145A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2549225A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP2008524317A (ja) * 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 腸溶コーティングされたアジスロマイシン多粒子
ATE444746T1 (de) * 2005-06-08 2009-10-15 Orion Corp Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen
NZ573823A (en) * 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
BRPI0718320A2 (pt) * 2006-10-27 2013-11-26 Janssen Pharmaceutica Nv Composições farmacêuticas secas granuladas e métodos para produzir as mesmas.
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
JP5292105B2 (ja) * 2007-01-11 2013-09-18 株式会社カネカ 補酵素ｑ１０粒子の製造方法
CA2723409C (en) * 2008-05-09 2016-11-08 Atacama Labs Oy Method and apparatus for dry granulation
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
JP5585920B2 (ja) * 2010-12-27 2014-09-10 富田製薬株式会社 粒子状製剤
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JPWO2023145486A1 (pt) * 2022-01-28 2023-08-03

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
TW271400B (pt) 1992-07-30 1996-03-01 Pfizer
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
ATE353014T1 (de) 1997-09-10 2007-02-15 Merial Ltd Verwendung von 9a-azaliden als antimikrobielle mittel für tiere
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
JP2002531409A (ja) * 1998-11-30 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
IL158591A0 (en) 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
ZA200405805B (en) 2006-05-31
NZ534234A (en) 2007-05-31
MXPA04007427A (es) 2004-10-11
US7438924B2 (en) 2008-10-21
AU2003201146B2 (en) 2008-04-17
WO2003063838A1 (en) 2003-08-07
NO20043644L (no) 2004-09-21
US20030228357A1 (en) 2003-12-11
KR20040079954A (ko) 2004-09-16
CN1646104A (zh) 2005-07-27
RU2004123624A (ru) 2005-04-10
AR038371A1 (es) 2005-01-12
RU2283092C2 (ru) 2006-09-10
EP1478347A1 (en) 2004-11-24
CO5611118A2 (es) 2006-02-28
PL372394A1 (en) 2005-07-25
CA2474809A1 (en) 2003-08-07
JP2005526020A (ja) 2005-09-02
TW200306865A (en) 2003-12-01
KR100676025B1 (ko) 2007-01-29

Similar Documents

Publication Publication Date Title
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
MX9404762A (es) Composiciones para inhalacion y proceso para su preparacion.
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
BRPI0409623A (pt) produto farmacêutico, método de preparação do mesmo e uso de substáncias na preparação do referido produto farmacêutico
TWI265812B (en) Pharmaceutical safety dosage forms
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
AR057636A2 (es) Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria
ES2187822T3 (es) Comprimidos de disgregacion rapida.
JP6009967B2 (ja) 固形製剤
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
BR122012014331A8 (pt) Formulações farmacêuticas
SI2729130T1 (en) Combined formulations of darunavir
HRP20100674T1 (hr) Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
BR0111868A (pt) Composições farmacêuticas
BRPI0608791B8 (pt) cápsulas para inaladores, uso de uma composição de polímero e processo para a secagem de pós para inalação
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
ATE447939T1 (de) Dosierungsformen enthaltend thyroidhormone und deren herstellungsverfahren
SV2002000574A (es) Composicion de eletriptan en forma de particulas ref. pcs10915aajr/bb

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.